Clinical trials: Tumor, Colorectal
Colorectal Cancer (CRC), Advanced Adenomas (AA)
Collection of Samples USOPTIVAL Study
A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC…
- Trial name
- NCT04792684
- Testing
- Optimization of Plasma Circulating Free-DNA (cfDNA) Marker Panel
- Where
- 16 sites in United States
- Volunteers
- 1,300 people, healthy volunteers welcome
- Sponsor
- Universal Diagnostics
Solid Tumor, Colorectal Cancer
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or…
- Conditions
- Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer
- Trial name
- NCT03872947
- Testing
- TRK-950, Irinotecan, Leucovorin
- Where
- 14 sites in United States, France
- Volunteers
- 138 people
- Sponsor
- Toray Industries, Inc
CRC (Colorectal Cancer)
Study of Ruxolitinib in Colorectal Cancer Patients
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
- Trial name
- NCT02119676
- Testing
- Ruxolitinib, Regorafenib
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 396 people
- Sponsor
- Incyte Corporation
Colorectal Cancer, Diverticulitis Colon
Seal-G MIST (Minimally Invasive Sealant/Spray Technology) System Safety Study [SEALAR Study]
The purpose of this study is to evaluate safety of Seal-G MIST System in reinforcing colorectal anastomosis, in subjects undergoing colorectal surgery.
- Trial name
- SEALAR (NCT03448874)
- Testing
- Seal-G MIST System
- Sponsor
- Sealantis Ltd.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.
- Conditions
- Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer
- Trial name
- NCT04383210
- Testing
- Seribantumab
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 54 people
- Sponsor
- Elevation Oncology
Diverticulum, Colon, Colorectal Neoplasms
Data Collection of Patients Treated With the ColonRing™ for the Creation of Circular Compression Anastomosis
The proposed study is a post marketing, observational, retrospective data collection intended to gather and record data on patients treated with the ColonRing™ device in routine clinical practice at a single center.
- Conditions
- Diverticulum, Colon, Colorectal Neoplasms, Crohn Disease, Colitis, Ulcerative
- Trial name
- RETROPRESS (NCT01301417)
- Testing
- ColonRing™
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- novoGI
Colorectal Cancer
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer: Continued Avastin Plus Chemotherapy After First Progression in Clinical Practice
This local, non-interventional, cohort study of patients with metastatic colorectal cancer (mCRC) will prospectively collect data from standard clinical practice of second-line treatment with chemotherapy plus Avastin…
- Trial name
- NCT02287597
- Where
- 4 sites in Croatia
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Colorectal Neoplasm
DS-8201a in Human Epidermal Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)
The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer.
- Trial name
- NCT03384940
- Testing
- DS-8201a
- Where
- 25 sites in United States, Italy and 3 more
- Volunteers
- 86 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Colorectal Cancer, Colorectal Adenoma
Protocol to Validate the Performance of the LifeKit® Prevent Colorectal Neoplasia Test for CRC Screening
The purpose of this study is to determine the sensitivity and specificity for LifeKit Prevent Colorectal Neoplasia Test for colorectal cancer (CRC) and for adenoma, including advanced adenoma.
- Trial name
- PREVENT (NCT04693546)
- Testing
- LifeKit Prevent Colorectal Neoplasia Test, FIT Test
- Where
- United States
- Volunteers
- 12,000 people, healthy volunteers welcome
- Sponsor
- Metabiomics Corp
Colorectal Cancer
Korean Red Ginseng in Treating Patients With Fatigue Caused by Chemotherapy for Colorectal Cancer
Korean Red Ginseng may improve fatigue in healthy subject. It is not yet known whether Korean Red Ginseng is effective compared with a placebo in chemotherapy.
- Trial name
- KRG (NCT02039635)
- Testing
- Korean Red Ginseng
- Where
- South Korea
- Volunteers
- 438 people
- Sponsor
- Korea Ginseng Corporation
Non Small Cell Lung Cancer, Advanced Solid Tumor
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as single agent and in combination with pembrolizumab in…
- Conditions
- Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma
- Trial name
- PRESERVE-001 (NCT04140526)
- Testing
- ONC-392, Pembrolizumab, Docetaxel
- Where
- 37 sites in United States, Australia
- Volunteers
- 733 people
- Sponsor
- OncoC4, Inc.
Colon Cancer Adenocarcinoma
A Phase Ib/II Study to Evaluate HLX43 Combined With HLX07 or Serplulimab in Patients With Advanced or Metastatic Colorectal Cancer
This study is a phase Ib/II study to evaluate the efficacy, safety and tolerance of HLX43 combined with HLX07 or Serplulimab in patients with advanced or metastatic colorectal cancer failed or intolerance to standard first-line…
- Trial name
- NCT07358585
- Testing
- HLX43 dose 1 + HLX07, HLX43 dose 2 + HLX07, HLX43 dose 3 + Serplulimab
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Shanghai Henlius Biotech
Locally Advanced Solid Tumor, Metastatic Tumor
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
The goal of this clinical trial is to test the safety of TST003 in patients with cancer. The main question[s] it aims to answer are: What is the recommended dose patients can safely receive? How long does this drug remain in the…
- Conditions
- Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
- Trial name
- NCT05731271
- Testing
- TST003
- Where
- 3 sites in United States
- Volunteers
- 111 people
- Sponsor
- Transcenta Therapeutics (Hangzhou) Co., Ltd.
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Familial Adenomatous Polyposis
Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)
This is a multicenter, two-part trial in participants with FAP.
- Trial name
- TUPELO (NCT05552755)
- Testing
- REC-4881
- Where
- 17 sites in United States
- Volunteers
- 67 people
- Sponsor
- Recursion Pharmaceuticals Inc.
Breast Cancer, Ovarian Cancer
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors
A Phase 1, open label, dose escalation and expanded cohort study of P-MUC1C-ALLO1 in adult subjects with advanced or metastatic epithelial derived solid tumors, including but not limited to the tumor types listed below.
- Conditions
- Breast Cancer, Ovarian Cancer, Non Small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT05239143
- Testing
- P-MUC1C-ALLO1 CAR-T cells, Rimiducid
- Where
- 14 sites in United States
- Volunteers
- 180 people
- Sponsor
- Poseida Therapeutics, Inc.
Colorectal Cancer
Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer
This study will evaluate the addition of enzastaurin to 5-FU (5-fluorouracil)/LV (leucovorin) plus bevacizumab in the maintenance of best response obtained with 6 cycles of first-line therapy consisting of 5-FU/LV + oxaliplatin…
- Trial name
- NCT00612586
- Testing
- Enzastaurin, Leucovorin (LV), 5-fluorouracil (5-FU)
- Where
- 26 sites in United States, Austria and 4 more
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
Colon Cancer, Breast Cancer
A Digimed Oncology PharmacoTherapy Registry
DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch (patch), and a mobile app, which records time-stamped medication type and dose alongside biometric activity.
- Conditions
- Colon Cancer, Breast Cancer, Rectal Cancer
- Trial name
- ADOPTR (NCT04088955)
- Testing
- DigiMeds
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Proteus Digital Health, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.